83 FR 7201 - National Cancer Institute; Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Federal Register Volume 83, Issue 34 (February 20, 2018)

Page Range		7201-7201
FR Document		2018-03322

Federal Register, Volume 83 Issue 34 (Tuesday, February 20, 2018)

[Federal Register Volume 83, Number 34 (Tuesday, February 20, 2018)]
[Notices]
[Page 7201]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2018-03322]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and/or contract proposals 
and the discussions could disclose confidential trade secrets or 
commercial property such as patentable material, and personal 
information concerning individuals associated with grant applications 
and/or contract proposals, the disclosure of which would constitute a 
clearly unwarranted invasion of personal privacy.

    Name of Committee: National Cancer Institute Special Emphasis 
Panel; Targeted Radiotherapy & Radiation-Induced Toxicity.
    Date: March 20, 2018.
    Time: 12:00 p.m. to 4:00 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Cancer Institute, Shady Grove, 9609 Medical 
Center Drive, Room 3W034, Rockville, MD 20850 (Telephone Conference 
Call).
    Contact Person: Ivan Ding, Ph.D., Scientific Review Officer, 
Program & Review Extramural Staff Training Office, Division of 
Extramural Activities, National Cancer Institute, NIH, 9609 Medical 
Center Drive, Room 7W236, Bethesda, MD 20892-9750, 240-276-6444, 
dingi@mail.nih.gov.

    Name of Committee: National Cancer Institute Special Emphasis 
Panel; R13 Conference Grant Review.
    Date: March 20, 2018.
    Time: 12:00 p.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Cancer Institute, Shady Grove, 9609 Medical 
Center Drive, Room 7W556, Rockville, MD 20850 (Telephone Conference 
Call).
    Contact Person: Bratin K. Saha, Ph.D., Scientific Review 
Officer, Program Coordination and Referral Branch, Division of 
Extramural Activities, National Cancer Institute, NIH, 9609 Medical 
Center Drive, Room 7W556, Bethesda, MD 20892-9750, 240-276-6411.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS)

    Dated: February 13, 2018.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-03322 Filed 2-16-18; 8:45 am]
 BILLING CODE 4140-01-P

Federal Register / Vol. 83, No. 34 / Tuesday, February 20, 2018 / Notices 7201

Contact Person: Ivan K. Navarro, Ph.D., Contact Person: Hiromi Ono, Ph.D., provisions set forth in sections
Scientific Review Officer, Office of Scientific Review Officer, Office of 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
Extramural Policy and Review, Division of Extramural Policy and Review, National
as amended. The grant applications
Extramural Research, National Institute on Institute on Drug Abuse, National Institutes
Drug Abuse, NIH, DHHS, 6001 Executive of Health, DHHS, 6001 Executive Boulevard, and/or contract proposals and the
Boulevard, Room 4242, MSC 9550, Bethesda, Room 4238, MSC 9550, Bethesda, MD 20892, discussions could disclose confidential
MD 20892, 301–827–5833, ivan.navarro@ 301–827–5820, hiromi.ono@nih.gov. trade secrets or commercial property
nih.gov. Name of Committee: National Institute on such as patentable material, and
Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Phase personal information concerning
Drug Abuse Special Emphasis Panel; II: Avenir Award Program for Genetics or individuals associated with grant
Identification of Genetic and Genomic Epigenetics of Substance Use Disorders
(DP1).
applications and/or contract proposals,
Variants by Next-Gen Sequencing in Non-
Human Animal Models (U01). Date: March 21, 2018. the disclosure of which would
Date: March 7, 2018. Time: 9:00 a.m. to 5:00 p.m. constitute a clearly unwarranted
Time: 1:00 p.m. to 4:00 p.m. Agenda: To review and evaluate grant invasion of personal privacy.
Agenda: To review and evaluate applications.
Place: Hyatt Regency Bethesda, One Name of Committee: National Cancer
cooperative agreement applications.
Bethesda Metro Center, 7400 Wisconsin Institute Special Emphasis Panel; Targeted
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive Avenue, Bethesda, MD 20814. Radiotherapy & Radiation-Induced Toxicity.
Boulevard, Rockville, MD 20852 (Telephone Contact Person: Ivan K. Navarro, Ph.D., Date: March 20, 2018.
Conference Call). Scientific Review Officer, Office of Time: 12:00 p.m. to 4:00 p.m.
Contact Person: Gerald L. McLaughlin, Extramural Policy and Review, Division of Agenda: To review and evaluate contract
Ph.D., Scientific Review Officer, Office of Extramural Research, National Institute on proposals.
Extramural Policy and Review, National Drug Abuse, NIH, DHHS, 6001 Executive Place: National Cancer Institute, Shady
Institute on Drug Abuse, NIH, DHHS, 6001 Boulevard, Room 4242, MSC 9550, Bethesda, Grove, 9609 Medical Center Drive, Room
Executive Blvd., Room 4238, MSC 9550, MD 20892, 301–827–5833, ivan.navarro@
3W034, Rockville, MD 20850 (Telephone
Bethesda, MD 20892–9550, 301–827–5819, nih.gov.
Conference Call).
gm145a@nih.gov. Name of Committee: National Institute on
Contact Person: Ivan Ding, Ph.D., Scientific
Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Multi-
Site Studies for System-Level Review Officer, Program & Review
Drug Abuse Special Emphasis Panel; NIDA Extramural Staff Training Office, Division of
Research ‘‘Center of Excellence’’ Grant Implementation of Substance Use Prevention
and Treatment Services (R01; R34). Extramural Activities, National Cancer
Program (P50).
Date: March 23, 2018. Institute, NIH, 9609 Medical Center Drive,
Date: March 13–15, 2018.
Time: 9:00 a.m. to 12:00 p.m. Time: 11:00 a.m. to 2:00 p.m. Room 7W236, Bethesda, MD 20892–9750,
Agenda: To review and evaluate grant Agenda: To review and evaluate grant 240–276–6444, dingi@mail.nih.gov.
applications. applications. Name of Committee: National Cancer
Place: Courtyard by Marriott Chevy Chase, Place: National Institutes of Health,
Institute Special Emphasis Panel; R13
5520 Wisconsin Avenue, Chevy Chase, MD Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone Conference Grant Review.
20815. Date: March 20, 2018.
Contact Person: Gerald L. McLaughlin, Conference Call).
Contact Person: Julia Berzhanskaya, Ph.D., Time: 12:00 p.m. to 5:00 p.m.
Ph.D., Scientific Review Officer, Office of
Scientific Review Officer, Office of Agenda: To review and evaluate grant
Extramural Policy and Review, National
Extramural Policy and Review, Division of applications.
Institute on Drug Abuse, NIH, DHHS, 6001
Extramural Research, National Institute on Place: National Cancer Institute, Shady
Executive Blvd., Room 4238, MSC 9550,
Drug Abuse, NIH, DHHS, 6001 Executive Grove, 9609 Medical Center Drive, Room
Bethesda, MD 20892–9550, 301–827–5819,
Boulevard, Room 4234, MSC 9550, Bethesda, 7W556, Rockville, MD 20850 (Telephone
gm145a@nih.gov.
MD 20892, 301–827–5840, Conference Call).
Name of Committee: National Institute on julia.berzhanskaya@nih.gov.
Drug Abuse Special Emphasis Panel; NIDA Contact Person: Bratin K. Saha, Ph.D.,
(Catalogue of Federal Domestic Assistance Scientific Review Officer, Program
Core Center of Excellence Grant Program
Program Nos.: 93.279, Drug Abuse and
(P30). Coordination and Referral Branch, Division
Addiction Research Programs, National
Date: March 15, 2018. Institutes of Health, HHS) of Extramural Activities, National Cancer
Time: 9:00 a.m. to 5:00 p.m. Institute, NIH, 9609 Medical Center Drive,
Agenda: To review and evaluate grant Dated: February 13, 2018. Room 7W556, Bethesda, MD 20892–9750,
applications. Natasha M. Copeland, 240–276–6411.
Place: Courtyard by Marriott Chevy Chase, Program Analyst, Office of Federal Advisory
5520 Wisconsin Avenue, Chevy Chase, MD (Catalogue of Federal Domestic Assistance
Committee Policy. Program Nos. 93.392, Cancer Construction;
20815.
[FR Doc. 2018–03324 Filed 2–16–18; 8:45 am] 93.393, Cancer Cause and Prevention
Contact Person: Gerald L. McLaughlin,
Ph.D., Scientific Review Officer, Office of BILLING CODE 4140–01–P Research; 93.394, Cancer Detection and
Extramural Policy and Review, National Diagnosis Research; 93.395, Cancer
Institute on Drug Abuse, NIH, DHHS, 6001 Treatment Research; 93.396, Cancer Biology
Executive Blvd., Room 4238, MSC 9550, DEPARTMENT OF HEALTH AND Research; 93.397, Cancer Centers Support;
Bethesda, MD 20892–9550, 301–827–5819, HUMAN SERVICES 93.398, Cancer Research Manpower; 93.399,
gm145a@nih.gov. Cancer Control, National Institutes of Health,
Name of Committee: National Institute on National Institutes of Health HHS)
Drug Abuse Special Emphasis Panel; Phase
II: Avenir Award Program for Research on National Cancer Institute; Notice of Dated: February 13, 2018.
sradovich on DSK3GMQ082PROD with NOTICES

Substance Abuse and HIV/AIDS (DP2). Closed Meetings Melanie J. Pantoja,
Date: March 19, 2018. Program Analyst, Office of Federal Advisory
Time: 8:00 a.m. to 5:00 p.m.
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as Committee Policy.
Agenda: To review and evaluate grant
applications. amended, notice is hereby given of the [FR Doc. 2018–03322 Filed 2–16–18; 8:45 am]
Place: Courtyard by Marriott Chevy Chase, following meetings. BILLING CODE 4140–01–P
5520 Wisconsin Avenue, Chevy Chase, MD The meetings will be closed to the
20815. public in accordance with the

VerDate Sep<11>2014 17:55 Feb 16, 2018 Jkt 244001 PO 00000 Frm 00066 Fmt 4703 Sfmt 9990 E:\FR\FM\20FEN1.SGM 20FEN1

Document Created: 2018-02-17 02:29:22
Document Modified: 2018-02-17 02:29:22

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Dates		March 20, 2018.
FR Citation		83 FR 7201